Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

Highlights: [•] Cervarix® demonstrated, in clinical trials, an overall 93.2% efficacy against CIN3+. [•] This efficacy translates into a large number of lives saved in all countries; an additional 18–34% more lives saved than expected based on protection against HPV-16/18 only. [•] Public health benefit also includes reduction in costs, morbidity and suffering. [ABSTRACT FROM AUTHOR]